Join
2seventy bio Inc.  When-Issued logo

TSVTV

NASDAQ

2seventy bio Inc. When-Issued

SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News0/Ratings0

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

TSVTV FAQ

5 questions
  • What does 2seventy bio Inc. When-Issued do?
    2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
  • Where does TSVTV stock trade?
    2seventy bio Inc. When-Issued (TSVTV) is listed on NASDAQ.
  • What sector and industry is TSVTV in?
    2seventy bio Inc. When-Issued operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • What companies are similar to TSVTV?
    Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare TSVTV side-by-side with any of them on Quantisnow.
  • How can I track TSVTV on Quantisnow?
    Quantisnow aggregates 2seventy bio Inc. When-Issued's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TSVTV to receive live email and push alerts on every new disclosure.